New target, new drug, old paradigm

Journal of Clinical Oncology

Volumn 22, Issue 12, 2004, Pages 2270-2272

  Hidalgo, Manuel ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; TEMSIROLIMUS; DRUG DERIVATIVE; RAPAMYCIN;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER INHIBITION; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG TOLERABILITY; EDITORIAL; HUMAN; KIDNEY CARCINOMA; PRIORITY JOURNAL; SIDE EFFECT; SIGNAL TRANSDUCTION; BREAST TUMOR; METHODOLOGY; NOTE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; HUMANS; RESEARCH DESIGN; SIROLIMUS;

EID: 2942722662     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.03.918     Document Type: Editorial

References (16)

1. Van Cutsem E, KP, Oettle H: Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol 21: 2002 (abstr 1430)
2. Raymond E, Alexandre J, Faivre S, et al: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336-2347, 2004
3. Dancey, JE: Clinical development of mammalian target of rapamycin inhibitors. Hematol Oncol Clin North Am 16:1101-1114, 2002
4. Sawyers CL: Will mTOR inhibitors make it as cancer drugs? Cancer Cell 4:343-348, 2003
5. Hidalgo M, Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19:6680-6686, 2000
6. Huang S, Bjornsti MA, Houghton PJ: Rapamycins: Mechanism of action and cellular resistance. Cancer Biol Ther 2:222-232, 2003
7. Atkins MB, et al: Randomized phase Il study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918, 2004
8. Mita MM, Mita A, Rowinsky EK: Mammalian target of rapamycin: A new molecular target for breast cancer. Clin Breast Cancer 4:126-137, 2003
9. Peralba JM, DeGraffenried L, Friedrichs W, et al: Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887-2892, 2003
10. Dudkin L, Dillins MB, Cheshire PJ, et al: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7:1758-1764, 2001
11. Boulay A, Zumstein-Mecker S, Stephan C, et al: Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64:252-261, 2004
12. Neshat MS, Melinghoff IK, Tran C, et al: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98:10314-10319, 2001
13. Podsypanina K, Lee RT, Politis C, et al: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A 98:10320-10325, 2001
14. Shi Y, Gera J, Hu L, et al: Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 62:5027-5034, 2002
15. Noh WC, Mondesire WH, Peng J, et al: Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10:1013-1023, 2004
16. Yu K, Toral-Barza L, Discafani C, et al: mTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8:249-258, 2001